Allen Patricia L
Known title: DirectorCIK: 0001348587
Allen Patricia L's purchase track record
Allen Patricia L has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/12/2026 | ZBIO | $500K | -27.6% | +11.8% | +14.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZBIO | ▲ Buy | Open Market | 4,160 | $110K | 2/13/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 5,700 | $139K | 2/12/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 5,000 | $133K | 2/12/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 5,000 | $119K | 2/12/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations
The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.